Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is 4basebio LSE:4BB Rising as Synthetic DNA Demand and Gene Therapy Partnerships Gain Attention?

4basebio LSE:4BB is among the notable UK-listed market movers on 21 September 2026, with the stock shown4.17% higher.

Ankur Sharma | 21 September 2026

Why Is Abingdon Health LSE:ABDX Rising as Diagnostic Test Growth and US Expansion Remain in Focus?

Abingdon Health LSE:ABDX is among the notable movers shown on 21 September 2026, with the share price gaining4.76%.

Ankur Sharma | 21 September 2026

Why Is AOTI LSE:AOTI in Focus Ahead of Its September Results and a Potential US Wound-Care Market Expansion?

AOTI LSE:AOTI is attracting attention after rising3.85% on 21 September 2026, with investors continuing to follow developments surrounding the company's TWO2 topical oxygen therapy platform and its potential expansion across the US healthcare market.

Ankur Sharma | 21 September 2026

What Is Driving Arecor Therapeutics LSE:AREC Higher as Ultra-Rapid Insulin and Oral Peptide Programmes Gain Attention?

Arecor Therapeutics LSE:AREC is among the notable movers shown on 21 September 2026, with the stock gaining4.47%.

Ankur Sharma | 21 September 2026

Why Is Cambridge Nutritional Sciences LSE:CNSL Rising as Diagnostic Testing and a Leaner Operating Model Gain Attention?

Cambridge Nutritional Sciences LSE:CNSL is among the notable UK market movers on 21 September 2026, with the share price shown3.57% higher.

Ankur Sharma | 21 September 2026

Ondine Biomedical Inc. Advances 4.37% as Positive LANTERN Results Strengthen Commercial Outlook

Ondine Biomedical shares rose by 4.37% as investors continued to assess the implications of positive topline results from the pivotal LANTERN study. The trial achieved its primary efficacy objective, demonstrating that nasal photodisinfection used alongside standard care reduced the risk of surgical-site infections compared …

Ankur Sharma | 21 September 2026

Genflow Biosciences Shares Build Momentum as Successful Longevity Trial Strengthens Commercial Potential

Genflow Biosciences shares rose by 4.10% as investors continued to assess the positive outcome from the company’s SLAB veterinary longevity trial. The study evaluated Genflow’s proprietary SIRT6 centenarian gene therapy in aged dogs and achieved its primary objective of reducing biological age as measured …

Ankur Sharma | 21 September 2026

How Surgical Product Demand Shapes the Opportunity for FTSE AIM All-Share Company Advanced Medical Solutions (AMS)

AMS designs, develops and manufactures a range of medical products, notably its tissue-adhesive products used to close wounds and surgical incisions, alongside sutures, sealants and advanced wound-care dressings. It sells both its own branded products and products supplied to partner companies. These are consumable …

Ankur Sharma | 21 September 2026

Why Commercial Scale Matters to the Food-Technology Story at FTSE AIM All-Share Company Agronomics (ANIC)

Agronomics builds a portfolio of holdings in companies pioneering cellular agriculture, the production of animal products such as meat and dairy, and related materials, using cell-culture and fermentation techniques instead of conventional farming. The thesis is that these approaches could, over time, offer more …

Ankur Sharma | 21 September 2026

Why the Route from Clinical Data to Commercial Sales Matters for AIM-Quoted Allergy Therapeutics (AGY)

Allergy Therapeutics develops and sells treatments that aim to tackle the cause of allergies through immunotherapy,Trainingthe immune system to tolerate allergens rather than merely suppressing symptoms. The company markets established products in several European countries and has been advancing a pipeline that includes a …

Ankur Sharma | 21 September 2026
Support

Hi! How can we help you today?

Loading…